Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy.
Fiche publication
Date publication
janvier 2016
Journal
Clinical Medicine Insights. Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier, Dr CURTIT Elsa, Dr MOUILLET Guillaume, Pr MOULIN Thierry
Tous les auteurs :
Verlut C, Mouillet G, Magnin E, Buffet-Miny J, Viennet G, Cattin F, Billon-Grand NC, Bonnet E, Servagi-Vernat S, Godard J, Billon-Grand R, Petit A, Moulin T, Cals L, Pivot X, Curtit E
Lien Pubmed
Résumé
Temozolomide and concomitant radiotherapy followed by temozolomide has been used as a standard therapy for the treatment of newly diagnosed glioblastoma multiform since 2005. A search for prognostic factors was conducted in patients with glioblastoma routinely treated by this strategy in our institution.
Mots clés
MRC neurological status, chemoradiotherapy, glioblastoma, temozolomide
Référence
Clin Med Insights Oncol. 2016 ;10:77-82